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Abstract 
Background: The assessment and treatment of Premenstrual Dysphoric Disorder (PMDD) in the 
female population is an important issue to be examined. Upward to thirty percent of all females’ 
report symptoms of moderate to severe PMDD. Proper assessment, identification and treatment 
of PMDD as a differential diagnosis by healthcare providers is essential for the effective 
treatment PMDD.  
Purpose: To provide evidenced based education to mental health professionals for the 
assessment and treatment of PMDD in order to help improve the quality of life for patient’s 
living with this disorder. 
Methods:  The PMDD education intervention took place at a inpatient psychiatric unit from 
October 2019 to April 2020 to a multidisciplinary team consisting of psychiatrists, psychologists, 
nurses, mental health counselors, and social workers during a Grand Rounds presentation at a 
state-run psychiatric facility in the Northeast. The participants completed a Likert survey that 
assessed the effectiveness of the presentation and the participant’s attitudes towards the treatment 
of PMDD. 
Results:  Post intervention, participants reported improved knowledge regarding assessment and 
evidence based modalities for the treatment of PMDD 
Keywords: Premenstrual Dysphoric Disorder, Adolescents, Self-harm and 
Depression 
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Considering Premenstrual Dysphoric Disorder  
as a Differential Diagnosis in the Psychiatric Population 
 An Educational Intervention Project 
Introduction 
 Up to 80 percent of women experience some form of Premenstrual Dysphoric Disorder 
(PMDD) (Yonkers et al., 2005). Symptoms occur principally during the late luteal phase of the 
menstrual cycle, but in the first 2 or 3 days of the follicular phase in about one-third. These 
symptoms can include: changes in mood, anxiety, decreased interest in pleasurable activities and 
impaired sleep (American Psychological Association, 2013). This project’s goal of educating 
mental health providers about PMDD is to increase awareness of the condition and to provide 
information and education regarding the patient’s menstrual health so that appropriate 
interventions may be implemented individually. Through ongoing assessment and treatment 
women who have this condition can have an improved quality of life. 
Background 
  “Premenstrual Dysphoric Disorder is a severe negative reaction to the natural rise and 
fall of estrogen and progesterone.” (International Association for Premenstrual Dysphoric 
Disorder, 2019). The symptoms of this disorder include not only physical manifestations such as 
bloating, acne, and mastalgia, but emotional dysregulation.  
According to Halbreich, Borenstein, Pearlstein & Kahn, (2003), almost six percent of 
young women live with this disorder. When this important disorder is not recognized or treated 
young women are placed at increased risk of mood instability, self-harm and agitation.  Without 
proper assessment and treatment young women are at risk for impaired well-being and health. 
Many healthcare providers come into contact with women who suffer with this disorder on a 
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daily basis. These healthcare providers have conversations, discussions and opportunities for 
patient education. So for the purpose of the DNP project, education will be done with mental 
health care providers so that conversations can be had with women about their reproductive well-
being and how it relates to mood. 
Problem Statement 
The relationship between the occurrence of Premenstrual Dysphoric Disorder 
(PMDD)and young women who self-harm and have emotional dysregulation is not clearly 
understood.  The purpose of this DNP project was to provide education to healthcare 
professionals so that there was an improvement in diagnosis, assessment and treatment of PMDD 
in the inpatient setting by education about the disorder, treatment standards and utilization of an 
evidenced based tools (Usher, 2102). It has been hypothesized by medical professional that 
changes in hormones can affect mood in women during child bearing years (Gosh, 2103). It is 
questioned whether these fluctuations in mood states can increase the likelihood of self-harm, 
agitation and mood lability. The DNP student provided education about assessment and 
treatment as well as how to create a dialogue with patients about PMDD to a multidisciplinary 
mental health care provider audience. 
Organizational “Gap” Analysis of Project Site  
 The project site provides treatment for 360 patients who have not been able to stabilize 
psychiatrically in a lower level of care. This site serves as the highest level for psychiatric care in 
the Commonwealth of Massachusetts. The patients admitted have psychiatric diagnoses that 
range from thought and mood disorders to Post-Traumatic Stress Disorder (PTSD). While 
PMDD may be part of a differential diagnosis, it is not formally assessed using an evidence 
based tool. Historically, the presence of this disorder has been minimized (Yonkers et al, 2005). 
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Currently, nursing staff at the hospital completes a detailed assessment at admission, but does not 
complete a reproductive health assessment and do not ask questions pertaining to mood and 
hormonal fluctuations. The goal of this project was to educate mental health professional staff to 
become familiar with this PMDD as a differential diagnosis in mental health care and for the 
mental health professional staff to become familiar with evidenced based tools that can be 
utilized in the inpatient setting, as well as diagnostic criteria and treatment options. These tools 
included scales that can be used by patients to rate their symptoms, as well as symptom rating 
scales that can be used in assessment by healthcare providers. In doing, this the health care 
provider will be better informed to advocate and educate their patient population 
Review of the Literature 
 The relationship between the occurrence of Premenstrual Dysphoric Disorder (PMDD) 
and young women is not clearly understood as a differential diagnosis. The purpose of this 
literature review was to examine some of the current evidence based research on the complex 
relationship between PMDD and related behaviors in young women and support the further need 
for proper education, assessment and treatment.  
Changes in hormones can affect mood states in women of child bearing years (Usher, 
2012). It is also now thought these changes may impact the emotional health of the young 
women and can lead to increased agitation and self-harm behaviors. (Yonkers et al, 2005) For 
the purpose of the analysis of the quality of the evidence used in the review of literature the 
Johns Hopkins Nursing Evidence-Based Practice Model (JHNEBP) is utilized. The JHNEBP is a 
tool that uses a three step process to examine the quality of evidence based literature and how it 
translates to practice (Newhouse, Dearholt, Poe, Pugh, and White, 2005). 
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The following databases were used to obtain to the journal articles reviewed: Google 
Scholar, PyschINFO, PUB MED. Terms used included Premenstrual Dysphoric Disorder, 
Adolescents, Emotional Dysregulation, Lability and Self-Harm. The results were limited to 
articles or research studies that have taken place over the past ten years, unless the article is 
clinically significant (as with the case with Yonkers, et al). Aspects such as culture or nation of 
origin of publication were included to look at this as shared phenomenon.  
Using the final inclusion criteria for the purpose of the literature review, over thirty 
journal articles were found to be appropriate to the needs of this educational intervention. The 
final inclusion criteria included articles from scholarly journals that were relevant to effects of 
PMDD on Mood.  All articles included for the purpose of this project were assessed using the 
JHNEBP 
In the evidence based studies that were reviewed, there appears to be a relationship 
between menstrual cycle, agitation, mood lability and self- harm. In a correlational study looking 
at the relationship between depression and relationship between Major Depression and PMDD 
(Corbsa et al, 2008) showed that Major Depression in itself can cause symptoms of PMDD.  
Furthermore, Corbsa et al, hypothesized that decrease in mood and increase in depression can led 
to thoughts of self-harm, agitation and suicidal ideation. 
Looking beyond a depressed mood state related to menses and self-harm, it can be 
supported that menses and bipolar disorder can contribute to self-harm actions and agitation. A 
case study by Gosh (2013), found that in bipolar disorder women could also have premenstrual 
exacerbations, causing diagnostic confusion.  When in a hypomanic or mixed episode state a 
patient may have showed impaired judgement leading to intentional or unintentional self-harm 
and agitation. 
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Saunders and Hawton (2006), evaluate the evidence between the relationship of menses 
to non- suicidal self-harm behaviors. They contributed this to the role of estrogen and the 
serotonergic system between the menstrual cycle and non-fatal suicidal behaviors and 
interactions between estrogen and the serotonergic system. Saunders and Hawton, conducted a 
systematic review of forty-five separate research studies on the effects of the menstrual cycle and 
suicidal ideation, self-harm and emotional dysregulation. In review of these studies, they 
observed that there is a relationship between cycles and self-harm, rather than a causal effect.  
     According to Faticia et al (2018), the relationship between psychosis and PMDD is 
evident because of the decline of estrogen during the late luteal phase of the menstrual cycle's 
late luteal phase, which can worsen psychosis. However, this study does not examine the effects 
of estrogen on mood and self-harm. But hypothesis the effects of estrogen on mental status 
decline. 
In qualitative study out of Lund University, in the United Kingdom, nineteen participants 
were interviewed about their healthcare providers understanding about PMDD found that most 
participants felt that their healthcare providers had a knowledge deficit about the treatment and 
consequences of PMDD on their patients (Jurvanen, 2017). This study further found that most 
women experiencing PMDD felt that their healthcare providers did not acknowledge how PMDD 
affected their daily functioning and work performance.  
Current best practice for treatment of this disorder include the use of oral contraceptive 
and SSRI’s (Yonkers et al, 2005). In a recent publication by the International Association for 
Premenstrual Disorders (2019), current recommendations include the potential incorporation of 
antidepressant medications such as Prozac, Paxil, or Celexa, these medications have been shown 
to have efficacy rate of Strong evidence of in the treatment of PMDD in many randomized 
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controlled trials are around 60-75%. Use of continuous oral contraceptives have been shown 
reduce PMDD symptoms in controlled trials 48% of time (Yonkers et al, 2005). Currently, 
studies are being completed with the use of continuous hormonal release IUDs such as mirena 
and low dose antipsychotics such as Seroquel. 
Why is understanding the relationship between menstruation, mood lability, agitation and 
self-harm important for the Mental Health Care provider? Barry (2018), believed that by utilizing 
an evidenced based tool that eventually one can predict changes in mood related to menses and 
reduced changes in mood, agitation and self-harm behaviors by delaying one’s menses (use of 
oral contraceptives) or by the addition of a SSRI. When we are able to better understand how 
lability of mood related to menses impact we can reduce the risk of our patients engaging in self-
harm behaviors. This reduction in self-harm behaviors and reduction of symptomology can 
provide relief from the agonizing nature of not being able to predict or stabilize one’s mood.  
Through further study of PMDD in the young female population the Mental Health Care 
provider can create opportunities for providing education to patients and encourage patients to 
take ownership for their own health and well-being by embracing their reproductive health. 
Evidence Based Practice:  
  Current Evidence Based Practice guidelines do not recognize PMDD as a disorder 
outside the United States.  As of now, the World Health Organization recommends that 
Premenstrual Dysphoric Disorder be recognized as a medical condition that is in need of further 
research and treatment (Craner, Sigmon, & McGillicuddy, 2014).  
According to Panay (2011), current best practice guidelines recommend that patient’s 
identified as being diagnosed with PMDD is treated by a multidisciplinary team that incorporates 
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medications, nutrition, exercise, and Cognitive Behavioral Therapy (CBT) to have the best 
outcome for management of symptoms. 
Theoretical Framework/Evidence 
 The Biopsychosocial theory takes a holistic approach to looking at the individual that 
encompasses the different components that make up wellness (Alfonso, 2004).  Current best 
practice guidelines state that PMDD should be treated by a multidisciplinary team and that the 
patient should be treated holistically and that complementary therapies are helpful for maximum 
alleviation of symptoms and wellness (Panay, 2011).  Chrisler (2008) describes the female 
menstrual cycle as being a “perfect process” that takes in account the female’s physiological 
status and how it can be affected by behaviors and experiences (pg.65). 
 According to Walker (1995), when we view PMDD through a Biopsychosocial model, we 
become better aware of the patient’s individual experiences and we gain a clearer understanding 
of their lived experience. Biopsychosocial theory takes into account the patient as a whole. It is a 
holistic approach that appreciates the different dynamics in the patient’s life that effect their 
health and wellbeing. 
Methods 
A Quality Improvement education intervention was implemented in order to educate 
mental health care providers regarding Premenstrual Dysphoric Disorder. During a recorded 
sixty-minute presentation offered at a hospital wide Grand Round, 30 healthcare providers were 
presented with how to properly assess for PMDD and gained knowledge on differential 
diagnosis, and appropriate treatment to reduce suffering to patients. 
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Goals, Objectives and Expected Outcomes 
The goals and objectives of this DNP project were: 
Goal: Mental Health Care Providers were able to gain knowledge in the signs and symptoms 
identification, assessment and holistic treatments of PMDD for patients with mental health 
disorders. 
Objectives and Outcomes: 
I.               Education- The participants were able to verbalize the signs and symptoms of PMDD 
after completing the Grand Rounds.   
II.               Assessment- All participants were trained on how to complete a PSST-A.   
III.              Collaboration- Reinforcement about the importance of assessment and treatment of this 
disordered by all providers involved in the patient’s treatment team. 
Expected Outcome:  resulted in increased participant awareness of PMDD as evidenced by the 
staff being able to verbalize signs and symptoms of PMDD by self-report on Likert survey.  
Ethical Considerations/Protection of Human Subjects 
The University of Massachusetts, Amherst (UMass) Internal Review Board (IRB) 
approval was obtained prior to initiating the educational intervention, quality improvement 
project. The results obtained from the data analysis was aggregated and did not include any 
potential participant identifiers. The data was scored on a password protected laptop computer 
that was only accessible by this DNP student. The risks to those participating in the project were 
no greater than those who are not currently being assessed for PMDD. All participants’ right to 
privacy of health information was protected by the Health Insurance Portability and 
Accountability Act of 1996 (HIPPA). 
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Implementation and Population 
      The implementation phase of this project started September 2019. The DNP student obtained 
approval via the education coordinator and ground rounds committee to conduct a presentation 
about PMDD criteria, diagnosis, assessment and treatment.  Specific Learning objectives were 
developed for the presentation with input from the hospital’s grand round committee.  
  In January 2020, the DNP student conducted a 60 -minute power point presentation on 
PMDD during a Grand Rounds presentation at a state run psychiatric inpatient facility in the 
Northeast. The audience consisted of psychiatry, psychology, nursing, social work and mental 
health. All Health Care Providers were eligible to received Continuing Education Units (CEUs) 
for attending the presentation. Of the 30 participants, seventeen returned completed surveys. The 
following table (Table 1) represents the breakdown of the Mental Health Providers disciplines 
that took part in the education intervention. 
Table 1 
Mental Health Discipline of Participants   
Discipline Participants Percentage 
Psychology 0 0.0% 
Psychiatry 4 23.53% 
Nursing 2 11.76% 
OT/Rehab 2 11.76% 
LMHC 1 5.88% 
Social Work 7 41.18% 
Other 1 5.88% 
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 The majority of the participants that completed the survey were non-nursing mental 
health care providers.  Of the 17 mental health care providers, 41% (n= 7) identified as Licensed 
Social workers, 23% Psychiatrist or APRNs (n= 4), 11% (2) Occupational Therapists, and one 
Licensed Mental Health Counselor.  
  The Premenstrual Symptom Screening Tool-Adolescent (PSST-A) version was utilized to 
assist in teaching participants on the assessment of the symptoms of Premenstrual Dysphoria 
Disorder. The PSST-A is an evidence based and reliable tool that helps healthcare workers 
evaluate the presence of Premenstrual Symptoms and how these symptoms impact the daily 
functioning of patients. Additionally, a patient tool kit was disseminated to all participants 
consisting of resources to assist in the diagnosis, assessment and treatment of patients (see 
Appendix E). The tool kit contents for patient education included copies of the PSST-A, diary 
card of symptomology, brochures on PMDD, and listings of web based support groups. 
 Following the presentation, all members of the multidisciplinary audience received a 
Healthcare Provider Survey sent to them by the writer via survey monkey shortly after the 
presentation and also one month later via email to assess change in clinical practice after the 
educational intervention was conducted.    
Measurement Instruments 
          In order to measure the outcomes of this DNP Project, the following instruments were 
used HealthCare Provider Quest and Follow Up one month post educational intervention Health 
Care Provider Questionnaire The first instrument was a DNP student developed survey 
(Appendix D) with eight Likert scale questions. A five point Likert scale of 1 to 5 was used to 
obtain opinions from the participants. The scores were given based upon the following numbers: 
1= strongly disagree; 2= disagree; 3= neither or N/A; 4= agree; and 5= strongly agree. The 
  
15 
survey was designed to illicit the opinions of the nursing staff on the usefulness and benefit of 
assessment and treatment of PMDD. Additionally, this survey queried the discipline of the 
audience member, attitudes towards discussing PMDD with their patients, the relevance of 
PMDD in the treatment of patients, and the usefulness of the grand rounds presentation. The 
following were the eight questions administered to the participants via Survey Monkey. 
1. Overall Rating of Educational Activity presentation quality 
2. Do you plan to make any changes in practice based on this educational intervention? 
3.  Are you able identify the signs and symptoms of PMDD after the presentation? 
4. Do you feel that you are more knowledgeable about the impact of PMDD on your 
patient’s health? 
5. The number of staff that feel that PMDD is an under recognized condition? 
6. Did you find the tool kit helpful? 
7. Do you feel that your patient’s benefit from being assessed for PMDD? 
8.  Do you feel more comfortable talking to your patients about their PMDD symptoms after 
the presentation? 
A second follow up survey was developed by the DNP student and sent out to all 
participants one month post educational intervention allowing them to provide comments via an 
anonymous Survey Monkey email on the educational intervention. This survey was to examine 
how the educational presentation informed their continued practice.  Two questions were asked 
of all participants to identify themes and viewpoints on the treatment of PMDD, which are 
included below: 
1. Have you incorporated assessing for PMDD into your practice based upon what you 
learned in the presentation? 
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2. Do you feel more confident in talking to your patients about PMDD since the 
presentation? 
 The two surveys were completed anonymously online via Survey Monkey. Descriptive 
statistics, such as frequency, mean, and median were used to analyze the data. Furthermore, the 
participants’ responses were analyzed utilizing these descriptive statistics to assess for 
knowledge improvement after the Grand Rounds presentation. Additionally, the Likert questions 
in the Health Care Provider questionnaires were scored to quantify the extent to which the Health 
Care Providers agreed with the questions asked.  
Results 
  The Presentation “Considering Premenstrual Dysphoric Disorder as Differential 
Diagnosis in the Psychiatric Population” was a sixty-minute educational presentation and 
intervention that took place at 360 bed inpatient psychiatric hospital in the Northeast. The 
participants that attended this intervention were mental health providers, working with patients 
with chronic mental health disorders. The data collected by the survey will be discussed in the 
subsequent sections which are divided by questions asked of the participants and their responses.  
Initial Survey Monkey Results 
1. Overall Rating of Educational Activity presentation quality 
The majority of participants viewed the presentation favorably, with 16 of the 17 participants 
reporting that the presentation was excellent with to very good, one out 17 of the participants 
indicated that the presentation of the educational intervention was fair. As a major goal and 
objective of the educational intervention, the DNP student wished to see increased awareness 
and education regarding PMDD amongst mental health care providers. This awareness of the 
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importance of making changes in practice was demonstrated by the participant’s desire to 
include assessment for PMDD in their standard of practice. 
2. Do you plan to make any changes in practice based on this educational intervention? 
70% (n= 15) of the participants indicated a plan to make changes in their practice to 
incorporate the assessment of PMDD into the care of patients. While 17% (n= 2) of 
participants did not feel the need to change their practice after the intervention. This may be 
related to their own practice currently incorporating assessment and treatment of patients 
with PMDD. 
3.  Do you feel that you have improved identification of signs and symptoms of PMDD 
after Presentation? 
The members of the multidisciplinary audience that attended were able to verbalize the signs 
and symptoms of PMDD after attending the Ground Rounds as evidenced, by all participants 
reporting that after the educational intervention that they felt increased awareness of PMDD 
was shown. Also, all participants (n= 17) were able to self-identify at least three signs and 
symptoms of PMDD.  While 88% (n= 16) of participants were able to identify and three 
evidence based approaches to the treatment of PMDD.  
4. Can you identify how PMDD impacts your Patients’ health and wellbeing? 
All participants (n= 17) report that they were able to identify two areas that PMDD can 
impact a patient’s co-morbid psychiatric illness. The participants were also asked if they 
believed that the information presents at the educational intervention utilized the most 
current and best evidence available. All participants also reported that they felt that the 
information that was presents used the best evidenced based materials and literature 
possible.  
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5. Do you feel that PMDD is an under recognized disorder that benefits from assessment? 
All participants reported that they felt patients could benefit from being assessed for PMDD. 
Furthermore, 88% (n= 16) felt that PMDD is an under recognized disorder that benefits from 
ongoing assessment and treatment. 
6.  Do you feel more comfortable in talking to your patients about their PMDD symptoms 
after the presentation?  
All participants (n=17) reported that they felt more comfortable talking to their patients 
about PMDD symptoms after the presentation.  To encourage continued conservation and 
assessment all participants received educational materials to take with them to help provide 
education to their patients about this disorder. These materials included record for the 
patients to assess their own symptoms, a PowerPoint copy of the presentation, a copy of the 
PSST-A, and patient education materials. 
7. Did you find the tool kit helpful? 
Regarding the helpfulness of the PMDD tool kit, 82% (n= 15) found the “tool kit” helpful 
and would use the resources provided to assess, treat and educate their patients. Conversely, 
two participants did not find the tool kit helpful, reporting that the font utilized on the 
handouts were too small to read.  
One month follow up Health Care Provider Survey Monkey Questionnaire 
1.Have you incorporated assessing for PMDD into your practice based upon what you 
learned in the presentation? 
At the one month follow up second survey, three of the thirty participants returned a follow 
up survey, it is unknown why there was limited participation These results showed that two 
of the three respondents have incorporated assessment of PMDD into their individual 
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practice with their patients. Additionally, these same three participants felt more confident in 
talking to their patients about PMDD as evidenced by reporting increased confidence in their 
assessment skills.   
3. Do you feel more confident in talking to your patients about PMDD since the 
presentation? 
 Increased interest in the topic of PMDD as a differential diagnosis in the psychiatric 
population was demonstrated, with all three participants reporting increased interest in 
continued education about PMDD. However, with limited data one month after the 
intervention it was difficult to see if the intervention impacted all the practice of the 
participants. 
Further information and dissemination of education related to the care of the PMDD 
patient needs to be clarified as limited data and feedback was able to be collected after the 
initial intervention. 
Discussion  
A presentation on PMDD took place during a sixty-minute Ground Rounds at a 360 bed 
inpatient psychiatric hospital in the Northeast.  The goal of this presentation was to provide 
evidenced based education to mental health professionals for the assessment and treatment of 
PMDD. It is through education that we can improve the quality of life for patient’s living with 
PMDD. After the presentation, all participants received a questionnaire to examine their views 
on PMDD. 
 The initial survey had good participation with 17 Mental Health Care Providers 
completing it. These Mental Health Care Providers received CEUs upon completion. However, 
at the one month follow up, a second survey was emailed to participants with limited returned 
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surveys by the Health Care Providers. Of the 17 participants, only three returned completed 
surveys.  Moreover, it is believed that the low return rate was due to the lack of incentive for 
providers to complete the second survey.  Nevertheless, the second survey assessing PMDD data 
resulted in the following themes discussed in subsequent paragraphs. 
Knowledge Deficit in the assessment and treatment of PMDD 
In the initial follow survey, 70% of the participants reported that they would change their 
practice after the presentation. In the follow up survey, all participants reported that incorporate 
assessment for PMDD into their individual practice. This response rate was an indication that the 
Health Care Providers pre intervention knowledge of the assessment of PMDD and treatment 
was limited. Also, this further indicated that the participants benefited from learning about the 
impact of PMDD on their patients. 
Under recognition of PMDD by Health Care Providers  
All Health Care Professionals that completed the initial survey reported that they believed 
that PMDD is an important disorder to assess for and treat for individuals with mental health 
disorders after the presentation. The Mental Health Providers also endorsed the concept that 
PMDD is not widely recognized as mental health disorder that impacts patient health and 
wellbeing. In reviewing the literature, most women experiencing PMDD felt that their healthcare 
providers did not acknowledge how PMDD affected their lives (Jurvanen, 2017). Through 
ongoing education of mental health care providers this under recognition could be reduced and 
the quality of care can be improved. 
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Education creates confidence in communication 
As indicated by the data collected in both the initial and follow up survey, all participants 
reported gained confidence in talking to their patients about assessment and treatments of 
PMDD. 
Walker (1995), stated that we must see our patients living with PMDD with a holistic and 
multidisplinary lens so we can communicate empathically with our patients. As evidenced by the 
participant feedback from survey further education and communication about PMDD is 
imperative in providing holistic care. Through effective communication patients can be more 
comfortable in disclosing their symptoms to their providers. 
Recommendations 
The importance of further study into the phenomenon of PMDD is essential. Through 
training healthcare providers how to properly assess for PMDD and understand the criteria for 
PMDD as a differential diagnosis, healthcare providers can provide appropriate treatment and 
reduce suffering to our patients, this is the goal of nursing. Additionally, it is recommended that 
ongoing education about the most current evidence based treatments and modalities for PMDD 
be reviewed on an annual basis with all Mental Health Care Professionals at the facility to 
maximize the benefits of this intervention 
 Premenstrual Dysphoric Disorder is a serious concern to the wellbeing of women of 
childbearing years. When PMDD is not treated properly there is an increased risk of harm to the 
patient. PMDD can cause mood instability, self-harm and agitation in some affected patients 
(Yonkers et al, 2007). For young women who are struggling with mental health issues such as 
Post-Traumatic Stress Disorder, Bipolar disorder or psychosis, PMDD can intensify these issues. 
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Conclusion 
The assessment and treatment of Premenstrual Dysphoric Disorder (PMDD) is an 
important issue to be examined. According to research, up to thirty percent of all females’ report 
symptoms of moderate to severe PMDD. Proper assessment and treatment of PMDD as a 
differential diagnosis in psychiatric assessment is essential for patients to receive adequate care. 
Without proper assessment and treatment, patients are at higher risk for impaired job 
performance and activities of daily living (Jurvanen, 2017). 
The goal of this DNP project was to increase awareness about the importance of 
assessing menstrual health so that appropriate interventions may be implemented.  By assessing 
for and treating PMDD we can improve the quality of life for our patients that may be 
experiencing mood lability or thoughts of self-harm due to hormonal sensitivity.   
. 
 
 
  
 
 
 
 
 
 
 
 
  
23 
References   
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental 
 disorders (DSM-5®). American Psychiatric Pub. 
Barry, L. (2018). A tool to track links between menstruation and mental health. Mental Health 
Practice, 21(9). 
Bertram, D. (2007). Likert scales. Retrieved November, 2, 2013. 
Csorba, J., Ferencz, E., Palaczky, M., Pali, E., Nagy, E., Horvath, A., & Vados, M. (2008). 
Clinical diagnoses and behavioral symptoms of Hungarian adolescent outpatients 
suffering from self-injurious behavior. European Psychiatry, 23, S246. 
Chrisler, J. C. (2008). The menstrual cycle in a biopsychosocial context. Psychology of  
women: A handbook of issues and theories, 400-439. 
Craner, J. R., Sigmon, S. T., & McGillicuddy, M. L. (2014). Does a disconnect occur between 
 research and practice for premenstrual dysphoric disorder (PMDD) diagnostic 
 procedures? Women & health, 54(3), 232-244. 
Delara, M., Ghofranipour, F., Azadfallah, P., Tavafian, S. S., Kazemnejad, A., &  Montazeri, A. 
(2012). Health related quality of life among adolescents with premenstrual disorders: a 
cross sectional study. Health and quality of life outcomes, 10(1), 1. 
Fatica, J. P., Jiwani, S., Salman, R., & Majeed, S. (2018). Premenstrual Psychosis in an 
 Adolescent: A Case Report. Clinical schizophrenia & related psychoses. 
Ghosh, S. (2013). Rapid cycling bipolar-II disorder presenting as hypomanic episodes 
 associated with menstruation: a case report. Sri Lanka Journal of Psychiatry, 4(2). 
Glenn, C., & DeNisco, S. (2006). Self-mutilation in adolescents: Recognizing a silent 
 epidemic. 
  
24 
Halbreich, U., Borenstein, J., Pearlstein, T., & Kahn, L. S. (2003). The prevalence, 
 impairment, impact, and burden of premenstrual dysphoric disorder 
 (PMS/PMDD). Psychoneuroendocrinology, 28, 1-23. 
Jurvanen, S. (2017). The Subjective Experience of Pre Menstrual Dysphoric Disorder 
 PMDD)-A qualitative study exploring consequences of PMDD symptoms in 
 relation to occupational and private life. 
Newhouse R, Dearholt S, Poe S, Pugh LC, White K. The Johns Hopkins Nursing  Evidence-
 based Practice Rating Scale. 2005. Baltimore, MD, The Johns Hopkins Hospital; Johns 
 Hopkins University School of Nursing.  
Panay, N. (2011). Management of premenstrual syndrome: evidence-based 
 guidelines. Obstetrics, Gynaecology & Reproductive Medicine, 21(8), 221-228. 
Pilver, C., Levy, B., Libby, D., & Desai, R. (2011). Posttraumatic stress disorder and trauma 
 characteristics are correlates of premenstrual dysphoric disorder. Archives of Women’s 
 Mental Health, 14(5), 383–393 
Saunders, K. E., & Hawton, K. (2006). Suicidal behavior and the menstrual cycle. 
 Psychological Medicine, 36(7), 901-912. 
Schiraldi, G. R. (2003). The post-traumatic stress disorder sourcebook: A guide to healing. 
(Adobe Digital Edition version). Doi: 10.1036/10071393722 
Singh, C., Jain, M., Jain, J., Solanki, R. K., Chaudhary, A., & Singh, K. (2017). A study of 
 psychiatric profile of premenstrual dysphoric disorder (PMDD) in college girls. Indian 
 Journal of Health & Wellbeing, 8(11), 1320–1324 
Steiner, M., Peer, M., Palova, E., Freeman, E. W., Macdougall, M., & Soares, C. N.   
  
25 
(2011). The Premenstrual Symptoms Screening Tool revised for adolescents (PSST-A): 
prevalence of severe PMS and premenstrual dysphoric disorder in adolescents. Archives 
of women's mental health, 14(1), 77-81. 
Usher, B. (2012). Estrogen fluctuation, estrogen based contraceptives and borderline 
 personality disorder traits (Doctoral dissertation, California State University, Northridge). 
Walker, A. (1995). Theory and methodology in premenstrual syndrome research. Social  
Science & Medicine, 41(6), 793-800. 
Wittchen, H. U., Perkonigg, A., & Pfister, H. (2003). Trauma and PTSD–An overlooked 
pathogenic pathway for Premenstrual Dysphoric Disorder?  Archives of Women’s Mental 
 Health, 6(4), 293-297. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
26 
Appendix A 
 
Cost Table 
 
Time for staff training 
Reproduction of Tool kits for staff and patient use=$100 
Use of Laptop –Provided by DNP student 
Event space= free providing by hospital 
Total cost for Quality Improvement Project= $100 
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Appendix C 
Timeline 
Table 1  
Task October November December January February March April 
Education 
and 
Presentation 
of Nursing 
staff on 
PMDD. 
Teaching of 
the PSST-A  
    X 
 
X 
 
 
    
Aggregation 
of the data 
 
  
X X X  
Post 
intervention 
meeting with 
collaborating 
nurses 
Analysis of 
the results 
and outcomes 
 
 
  
  X 
 
 
X 
 
Presentation 
of the results 
to nursing 
and program 
staff 
 
  
   X 
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Appendix D 
Healthcare Provider views on Premenstrual Dysphoric Disorder Assessment 
Please complete the following survey with specific regard to the above enquiry, by placing a 
circle on the appropriate response that best applies to you. Select only one response per 
question. The responses are on a 5-point Likert scale with 1= strongly disagree; 2= disagree; 3= 
neither or N/A; 4= agree; and 5= strongly agree. Please do not write your name or date of birth 
on this survey. All responses are kept confidential.  
1.  Do you feel that PMDD is an under recognized condition? 
Strongly disagree disagree neither agree  strongly agree 
 
 
2. Do think that your patient’s benefit from being assessed for PMDD? 
Strongly disagree disagree  neither  agree  strongly agree 
 
 
3. Do you feel comfortable talking to a patient about their PMDD symptoms?  
 
Strongly disagree disagree  neither  agree  strongly agree 
 
4. Do you feel that your knowledgeable about PMDD prior to attending this presentation? 
 
Strongly disagree disagree  neither  agree  strongly agree 
 
5. Did you find the handouts and tool kit helpful for you and your patients” 
 
Strongly disagree disagree  neither  agree  strongly agree 
 
6. Do you feel that your patients would benefit from educational materials about PMDD? 
Strongly disagree disagree  neither  agree  strongly agree 
 
7. What is your discipline? 
 
Psychiatry Psychology   OT/Rehab  MHC/MHW    Nursing 
 
7. Comments 
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Appendix F 
 
Evidenced Based Literature Tool Kit for Professionals 
 
Evidence-Based Management of 
Premenstrual Disorders (PMDs)  
Note: this guide is intended primarily as a resource for health care providers. 
If you are a patient, we recommend you also check out our treatment options 
page designed for patients at iapmd.org/treatment-options.  
Premenstrual disorders such as premenstrual dysphoric disorder (PMDD) and 
premenstrual exacerbation (PME) of psychiatric disorders are complex to 
diagnose and treat. Below, we provide guidelines to help health care 
providers educate and treat their patients effectively.  
Assessment and Diagnosis of PMDs: Ultimately, each patient with 
premenstrual symptoms is unique, and deserves a compassionate health care 
provider who will work with them to find an effective treatment--or set of 
treatments-- for their unique needs. Given that PME often predicts poor 
response to first-line PMDD treatments (see below), prospective diagnosis 
using two months of daily symptom ratings is recommended to differentiate 
between PMDD (symptoms present only premenstrual), PME (symptoms 
always present but worsened premenstrual), and non-cyclical symptoms. 
Daily ratings can also be continued in the context of treatment in order to 
evaluate effectiveness over time. A daily symptom rating form can be 
downloaded at https://iapmd.org/provider-resources. Standardized scoring of 
these daily ratings to determine diagnosis can be accomplished using the C-
PASS scoring system available at https://iapmd.org/c-pass. Please note that it 
is possible to have both PMDD (five symptoms that are present only in the 
luteal phase) and also PME of other underlying disorders.  
Treatment of PMDs: Since this is a relatively new area of medical science, 
the number of randomized controlled trials for PMDs remain relatively small. 
However, several treatments have been found to be effective, and more are 
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currently under investigation. Many patients utilizing IAPMD services have 
already tried many of the treatments below with no relief, whereas others 
have tried none. The purpose of this page is not to provide a “one-size-fits-
all” recommendation for the treatment of premenstrual disorders; rather, it is 
to help those seeking information about effective treatments by reviewing the 
best evidence about general efficacy and safety of each treatment in those 
with premenstrual disorders.  
Please visit iapmd.org for more information and resources. This guide was 
prepared by the IAPMD Clinical Advisory Board, under the direction of Dr. 
Tory Eisenlohr-Moul.  
  
© 2019 International Association for Premenstrual Disorders 
http://iapmd.org | updated March 11, 2019  
Evidence-Based Management of Premenstrual Disorders 
(PMDs) page 2  
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THE CLEVELAND CLINIC 
Home / Health Library / Articles 
I. Premenstrual Dysphoric Disorder (PMDD) 
PMS is related to a variety of physical and psychological symptoms that occur just before your 
menstrual period. Premenstrual dysphoric disorder (PMDD) is a severe form of PMS. 
1. What is PMS? 
Premenstrual syndrome (PMS) is a medical condition that affects some women of childbearing 
age. More than one in three women suffer from PMS. One in 20 suffer so severely that their 
lives are seriously affected. PMS is related to a variety of physical and psychological symptoms 
that occur just before the menstrual period. 
2. What causes PMS? 
The exact cause of PMS is unknown, but it seems to be related to the fluctuating levels of 
hormones (including estrogen and progesterone) that occur in preparation for menstruation. 
3. What are the symptoms of PMS? 
There are many symptoms of PMS, and the number and severity of symptoms vary from 
woman to woman. In addition, the severity of the symptoms can vary from month to month. 
Common symptoms of PMS include: 
● Bloating 
● Breast tenderness 
● Weight gain 
● Trouble concentrating 
● Headaches/backaches 
● Skin problems/acne 
● Fatigue 
● Tearfulness 
● Irritability/aggression 
● Anxiety 
● Mood swings and/or depression 
4. How is PMS diagnosed? 
There is no single test to diagnose PMS. It is a clinical diagnosis which is made by discussing 
your concerns with your doctor. However, there are some strategies your doctor may use to 
help diagnose PMS. These include: 
PMS symptoms diary — Your doctor may ask you to keep a diary to assess the frequency and 
severity of symptoms. By doing this, you can see if your symptoms correspond to certain times 
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in your monthly cycle. While your symptoms may vary from month to month, a trend likely will 
appear after tracking your symptoms for a few months. Sometimes women are surprised to 
find that the symptoms do not seem to vary with the fluctuation of their hormonal cycles. 
Women who have many of the emotional symptoms throughout the month may actually suffer 
from depression and/or anxiety. Making a correct diagnosis is the most important first step 
towards feeling better. 
Thyroid testing — Because thyroid disorders are common in women of childbearing age, and 
some of the symptoms of PMS—such as weight gain, depression, fatigue—are similar to 
symptoms of thyroid disorders, your doctor may order a test to evaluate thyroid function. This 
can help to rule out a thyroid disorder as a cause of your symptoms. 
5. How is PMS treated? 
Treatment for PMS is based on relieving symptoms. Treatment begins with a thorough 
assessment of your symptoms, as well as the impact of them on your daily life. 
Education — You will be better able to deal with your symptoms if you can relate how you're 
feeling to your menstrual cycles, knowing that you will feel better once your period starts. 
While symptoms may vary from month to month, the symptoms diary mentioned above can 
give you a good idea of how your periods affect your physical health and moods. Learning how 
to cope with the problems in your life may help relieve the stress and irritability you feel before 
your period. If you experience severe anxiety, irritability, or depression, counseling and/or 
medication may be helpful. 
Nutrition — A healthy diet is important to overall physical and mental wellness. Making 
changes in your diet—including reducing the amount of caffeine, salt and sugar and staying 
well-hydrated with water and light juices—may help relieve symptoms of PMS. A number of 
vitamin supplements are often taken to try to help PMS symptoms, including vitamin B6, 
vitamin E, calcium, and magnesium. However, none of these supplements have been shown in 
well-designed studies to be better than placebo (sugar pills or dummy pills, which can help 30 
percent of the time without an active ingredient). Talk to your doctor about the safety of trying 
calcium or magnesium supplements for you. Excess vitamin E or vitamin B6 is usually 
discouraged due to studies showing concerns about side effects, especially with vitamin B6. 
This vitamin can cause permanent nerve damage in women with daily doses in excess of 50 mg 
per day. It is best to try to get your vitamins by eating a diet rich in unprocessed fruits and 
vegetables. 
Exercise — Like a healthy diet, regular exercise can improve your overall health. It also can help 
relieve and help you cope with the monthly symptoms associated with PMS, especially 
dysmenorrhea (painful cramping and bloating). 
Medications — Over-the-counter pain relievers—such as aspirin and ibuprofen—may help 
relieve symptoms such as headache, backache, cramps, and breast tenderness. Make sure you 
have no contraindications such as peptic ulcer disease or kidney disease before using many pain 
relievers. Medications may be prescribed in cases of depression or anxiety that are disruptive to 
a woman’s lifestyle. Birth control pills and other hormonal contraceptives can help by 
controlling the hormonal fluctuations of the monthly cycle. 
  
43 
6. Can PMS be prevented? 
PMS itself cannot be prevented, but through education and appropriate treatment of 
symptoms, most women can find relief. A healthy lifestyle—including exercise and a proper 
diet—also can help a woman better manage the symptoms of PMS. 
7. What is PMDD? 
Premenstrual dysphoric disorder (PMDD) is a severe form of PMS. The symptoms of PMDD are 
similar to those of PMS, but are severe enough to interfere with work, social activities, and 
relationships. 
8. How is PMDD diagnosed? 
PMDD is diagnosed when at least five of the following symptoms occur seven to 10 days before 
menstruation and go away within a few days of the start of the menstrual period: 
● Mood swings 
● Marked anger 
● Irritability 
● Tension 
● Decreased interest in usual activities 
● Fatigue 
● Change in appetite 
● Sleep problems 
● Physical problems, such as bloating 
Before a doctor makes a diagnosis of PMDD, he or she will rule out other emotional disorders—
such as major depression or panic disorder—as the cause of the symptoms. In addition, 
underlying medical or gynecological conditions (such as endometriosis, fibroids, menopause, 
and hormonal problems) that could account for symptoms must be ruled out. 
9. How common is PMDD? 
PMDD occurs in 3 to 5 percent of menstruating women. Women with a personal or family 
history of mood disorders—including major depression or postpartum depression—are at 
greater risk for developing PMDD. 
10. What causes PMDD? 
As with PMS, the exact cause of PMDD is not known. Most researchers, however, believe PMDD 
is brought about by the hormonal changes related to the menstrual cycle. Recent studies have 
shown a connection between PMDD and low levels of serotonin, a chemical in the brain that 
helps transmit nerve signals. 
Certain brain cells that use serotonin as a messenger are involved in controlling mood, 
attention, sleep and pain. Therefore, chronic changes in serotonin levels can lead to PMDD 
symptoms. 
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11. How is PMDD diagnosed? 
Clinical evaluation should include a comprehensive review of the patient's symptoms and 
medical history, a physical exam, a gynecologic exam, and basic laboratory tests as needed. 
Psychiatric evaluation should focus on symptoms of depression, seasonal variation of 
depression (looking for worsening in the winter), alcohol and drug use, early victimization and 
trauma, family history of affective disorder (a group of disorders characterized by a disturbance 
of mood), alcoholism, and current situational stresses. 
12. How is PMDD treated? 
Many women gain relief from the symptoms of PMDD with education and lifestyle changes 
including exercise, vitamins, and a caffeine-free diet. Medications, including anti-depressants 
like selective serotonin reuptake inhibitors (SSRIs), may be used to treat the emotional 
symptoms of PMDD. Hormonal contraceptives may help, though it is important to be patient 
until a right fit for the woman’s body chemistry can be found. The optimal hormonal 
option/method can vary between each person. The FDA has approved the birth control pill Yaz® 
for the treatment of PMDD. However, other oral contraceptives may also help a woman with 
PMDD. In addition, individual and group counseling, and stress management can be beneficial 
in helping a woman cope with PMDD. 
SHARE  Facebook Twitter LinkedIn EmailPrint 
13. Related Institutes & Services 
(1) Ob/Gyn & Women's Health Institute 
Find the latest information on Women’s Health, including the use of minimally invasive surgical 
techniques, treatments for infertility, menstrual disorders, urogynecology and pelvic floor 
disorders, menopause and more. 
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support 
our mission. We do not endorse non-Cleveland Clinic products or services. Policy 
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